Jyske Realkredit A/S
To Nasdaq Copenhagen A/S 22 March 2021
Announcement no. 32/2021
Preliminary data on early redemptions (prepayments)
Pursuant to S. 24 of the Capital Markets Act, we hereby publish preliminary data on early redemptions (prepayments) in bonds issued by Jyske Realkredit. Please find the data in the attached file.
The information will also be available on Jyske Realkredit’s web site at jyskerealkredit.com.
For further information about format of data and content of the file we refer to the web site of Nasdaq at www.nasdaqomxnordic.com.
Questions may be addressed to Christian Bech-Ravn, Head of Investor Relations, tel. (+45) 89 89 92 25.
Yours sincerely
Jyske Realkredit
Please observe that the Danish version of this announcement prevails
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Alveus Therapeutics Inc23.1.2026 13:30:00 CET | Press release
Alveus Therapeutics Announces FDA Clearance of IND and First Patient Dosed in Phase 1b Trial of ALV-100 for Obesity
LOWRISC C.I.C.23.1.2026 13:28:00 CET | Press release
OpenTitan Introduces New Membership Tiers and Deliverables to Accelerate Deployment
Investeringsforeningen C Worldwide23.1.2026 13:20:27 CET | Pressemeddelelse
Opdatering af forventede udbytter for regnskabsåret 2025
Plug Power, Inc.23.1.2026 13:00:00 CET | Press release
Plug Power Completes Installation of 100 MW GenEco Electrolyzer Units at Galp’s Sines Refinery
OKYO Pharma LTD23.1.2026 13:00:00 CET | Press release
FDA Approves Compassionate Use of Urcosimod (0.05%) for the Treatment of Neuropathic Corneal Pain
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
